Cargando…

Superior clinical outcomes in patients with non-small cell lung cancer harboring multiple ALK fusions treated with tyrosine kinase inhibitors

BACKGROUND: Patients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) fusions may benefit from ALK-tyrosine kinase inhibitors (ALK-TKIs). However, few studies have analyzed the clinical outcome in patients harboring multiple ALK fusions, including double or triple A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Qi, Zhang, Yuanyuan, Wang, Yongsheng, Desai, Aakash, Tan, Sihan, Huang, Qin, Pu, Xin, Tian, Panwen, Li, Yalun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579835/ https://www.ncbi.nlm.nih.gov/pubmed/37854161 http://dx.doi.org/10.21037/tlcr-23-484

Ejemplares similares

A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance
por: Wang, Ye, et al.
Publicado: (2019)

Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
por: Zeng, Hao, et al.
Publicado: (2021)

A novel SLC8A1-ALK fusion in lung adenocarcinoma confers sensitivity to alectinib: A case report
por: Deng, Ling, et al.
Publicado: (2022)

Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy
por: Kyi, Chrisann, et al.
Publicado: (2021)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases
por: Pearson, Joel D., et al.
Publicado: (2012)

Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report
por: Wang, Zhan, et al.
Publicado: (2022)

Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma
por: Hu, G, et al.
Publicado: (2017)

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
por: Yang, Xiaobo, et al.
Publicado: (2022)

Characteristics of Renal Cell Carcinoma Harboring TPM3-ALK Fusion
por: Woo, Chang Gok, et al.
Publicado: (2020)

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
por: Schrock, Alexa B, et al.
Publicado: (2020)

High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in ALK-Rearranged Non-Small Cell Lung Cancer
por: Tian, Xia, et al.
Publicado: (2023)

ALK: a tyrosine kinase target for cancer therapy
por: Holla, Vijaykumar R., et al.
Publicado: (2017)

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors
por: Kwon, Minsuk, et al.
Publicado: (2022)

Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein
por: Kawai, Hidetsugu, et al.
Publicado: (2019)

Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement
por: Choi, Se Hoon, et al.
Publicado: (2017)

Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy
por: Wu, Jinchun, et al.
Publicado: (2021)

ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
por: Lovisa, Federica, et al.
Publicado: (2015)

The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability
por: Lobello, Cosimo, et al.
Publicado: (2018)

The neuronal receptor tyrosine kinase Alk is a target for longevity
por: Woodling, Nathaniel S., et al.
Publicado: (2020)

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
por: Liu, Dazhi, et al.
Publicado: (2018)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Responses to ALK Inhibitor Treatments in a Patient with Non-Small Cell Lung Cancer Harboring a Novel HPCAL1-ALK Fusion Variant: A Case Report
por: Wang, Ruixiao, et al.
Publicado: (2020)

Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors
por: Gibson, Amanda J.W., et al.
Publicado: (2021)

Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma
por: Zheng, Zhe-Rong, et al.
Publicado: (2023)

STUMP un“stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion
por: Subbiah, Vivek, et al.
Publicado: (2015)

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene
por: Tanaka, Hisashi, et al.
Publicado: (2012)

Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions
por: Dai, Yinghuan, et al.
Publicado: (2022)

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells
por: Verdura, Sara, et al.
Publicado: (2022)

Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring ALK-IGFBP5 fusion
por: Zhao, Ting, et al.
Publicado: (2023)

Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib
por: Hayashi, Nobuyoshi, et al.
Publicado: (2017)

Inflammatory Myofibroblastic Tumor of the Upper Airways Harboring a New TRAF3-ALK Fusion Transcript
por: Di Ruscio, Valentina, et al.
Publicado: (2021)

Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors
por: Sim, Jongmin, et al.
Publicado: (2018)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report
por: Hu, Han, et al.
Publicado: (2022)

Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces
por: Huang, Hao
Publicado: (2018)

METB-03. THE DISTINCT GENOMICS OF HIGH-GRADE INFANT GLIOMAS AMONG PEDIATRIC GLIOMAS HARBORING RECEPTOR TYROSINE KINASE FUSIONS
por: de Biagi-Junior, Carlos A O, et al.
Publicado: (2023)

The Receptor Tyrosine Kinase Alk Controls Neurofibromin Functions in Drosophila Growth and Learning
por: Gouzi, Jean Y., et al.
Publicado: (2011)

Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review
por: Desai, Aakash, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6bdhmls5avrmn39jtovofh5jfc